Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
Université Paris-Saclay · Institut Gustave Roussy · +32 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
764
total citations
- FWCI
- 103.50
- Percentile
- 100%
- References
- 30
Citations per year
Authors
33- KFKarim FizaziCorresponding
Université Paris-Saclay, Institut Gustave Roussy
- SFStéphanie Foulon
Inserm, Université Paris-Saclay, Institut Gustave Roussy
- JCJoan Carles
Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology
- GRGuilhem Roubaud
Institut Bergonié
- RMRay McDermott
St. Vincent's University Hospital, Cancer Trials Ireland
Topics & keywords
Topics
Keywords
- Docetaxel
- Medicine
- Prostate cancer
- Prednisone
- Abiraterone
- Androgen deprivation therapy
- Oncology
- Castration
No related works found for this paper.